-->
Consumption of fish oil
was associated with decreased incidence of cardiovascular events with effects
being most pronounced in patients with hypertension.
Lifestyle modification and dietary
supplementation have long been recognized as potential avenues of additional
therapeutic options to manage and prevent cardiovascular disease (CVD).
Fish oil and omega 3 fatty acid supplementation have previously been recognized
as products that could potentially prevent CVD and have widespread usage
globally despite follow-up investigations providing inconclusive results.
To better characterize its suitability for usage in the general population, researchers conducted a large-scale cohort study published in the BMJ consisting of 427,678 participants aged 40 to 69 in the UK investigating the associations between fish oil supplementation with all-cause mortality, CVD mortality, and CVD events, consisting of strokes and myocardial infarction. Median follow up times were 9 years for mortality outcomes and 8.1 years for CVD events.
Compared to controls, the cohort of 133,438 participants self-reporting habitual use of fish oil supplements had lower hazard ratios for all-cause mortality (0.87; 95% CI 0.83 – 0.90), CVD mortality (0.84; 95% CI, 0.78 – 0.91), and CVD events (0.93; 95% CI, 0.90 – 0.96). The effect of CVD event mitigation was most pronounced with patients with hypertension. Results were independent of possible confounding risk factors such as sex, BMI, physical activity, and diet.
Findings from the study provide further evidence to suggest a role for fish oil supplementation in providing a marginal benefit for CVD management and the prevention of mortality from all causes and CVD.
To better characterize its suitability for usage in the general population, researchers conducted a large-scale cohort study published in the BMJ consisting of 427,678 participants aged 40 to 69 in the UK investigating the associations between fish oil supplementation with all-cause mortality, CVD mortality, and CVD events, consisting of strokes and myocardial infarction. Median follow up times were 9 years for mortality outcomes and 8.1 years for CVD events.
Compared to controls, the cohort of 133,438 participants self-reporting habitual use of fish oil supplements had lower hazard ratios for all-cause mortality (0.87; 95% CI 0.83 – 0.90), CVD mortality (0.84; 95% CI, 0.78 – 0.91), and CVD events (0.93; 95% CI, 0.90 – 0.96). The effect of CVD event mitigation was most pronounced with patients with hypertension. Results were independent of possible confounding risk factors such as sex, BMI, physical activity, and diet.
Findings from the study provide further evidence to suggest a role for fish oil supplementation in providing a marginal benefit for CVD management and the prevention of mortality from all causes and CVD.
No comments:
Post a Comment